Comprehensive Diagnostic Program for Medically Underserved Women With Abnormal Breast Screening Evaluations in an Urban Population

• Published in: Mayo Clinic proceedings Vol. 84; no. 4; pp. 317 - 322
• Main Authors: Palmieri, Frances M., MSN, Deperi, Elizabeth R., MD, Mincey, Betty A., MD, Smith, Judith A., BSN, Wen, Lonnie K., PhD, Chewar, Deborah M., RN, Abaya, Reza, RN, Colon-Otero, Gerardo, MD, Perez, Edith A., MD
• Format: Journal Article
• Language: English
• Published: 2009
• Subjects: Internal Medicine; ductal carcinoma in situ; CDC; Centers for Disease Control and Prevention; DCIS; National Breast and Cervical Cancer Early Detection Program; NBCCEDP; BI-RADS; Breast Imaging Reporting and Data System
• ISSN: 0025-6196
• DOI: 10.4065/84.4.317

OBJECTIVE To institute a patient navigator program for underinsured women to eliminate delays in diagnostic resolution of abnormal screening mammograms, provide services for abnormalities noted during breast cancer screening, describe demographic and clinical characteristics of enrollees, and assess postscreening follow-up care. PATIENTS AND METHODS Coordinators from area health departments worked with a navigator nurse at Mayo Clinic Cancer Center in Jacksonville, FL, to refer patients for additional diagnostic services, including diagnostic mammography, ultrasonography, ultrasonography-guided biopsy, stereotactic biopsy, breast magnetic resonance imaging, and biopsy guided by magnetic resonance imaging. Women with abnormal screening mammograms (Breast Imaging Reporting and Data System [BI-RADS] category 4 or 5) or palpable suspect breast masses were eligible. Data were extracted from clinical service records. Timeliness of postscreening follow-up was assessed. RESULTS The study enrolled 447 women from June 30, 2000, to December 29, 2006. Data on the time from screening to diagnosis were available for 399 women, and median time from detection of screening abnormality to diagnosis was 37 days. Time between screening and diagnosis was 60 days or less for 325 (81%) of the 399 women for whom data were available and for 60 (82%) of the 73 women with BI-RADS category 4 or 5 assessments. Both of these percentages exceeded the Centers for Disease Control and Prevention quality benchmark of 75%. Mean time from study enrollment to diagnosis was 2 days for women with BI-RADS category 3 or 4 assessments and 7 days for women with BI-RADS category 5 assessments. CONCLUSION This program demonstrated a successful collaboration between an academic medical center and community health centers. Most women with BI-RADS category 4 or 5 assessments received a diagnosis within 60 days of screening.